<< Back to podcast list Strategic Partner(s) Dr. Caron Tribute Part 3 About Marc Caron Dr.

<< Back to podcast list Strategic Partner(s) Dr. Raul Gainetdinov About Dr.

<< Back to podcast list Strategic Partner(s) Dr. Nyla Naim, Dr. Michael Lemieux & Dr.

<< Back to podcast list Strategic Partner(s) Dr.

<< Back to podcast list Strategic Partner(s) Dr. Davide Calebiro About Dr.

<< Back to podcast list Strategic Partner(s) Dr. Nariman Balenga About Dr.

<< Back to podcast list Strategic Partner(s) Dr. Sudarshan Rajagopal About Dr.

<< Back to podcast list Strategic Partner(s) Inês Pinheiro, Monserrat Avila Zozaya & Yamina Berchiche

<< Back to podcast list Strategic Partner(s) Chris Langmead Chris Langmead is Professor, Deputy Director

<< Back to podcast list Strategic Partner(s) Dr. Kathleen Caron About Kathleen M. Caron Kathleen M.

<< Back to podcast list Strategic Partner(s) Dr. Stephen Ferguson About Dr. Stephen Ferguson Dr.

<< Back to podcast list Strategic Partner(s) Dr. Timo De Groof About Dr. Timo De Groof Dr.

. << Back to podcast list Strategic Partner(s) Randy Hall: Adhesion GPCRs and the Tail Nobody Wanted neurodegenerative condition sits on the C terminus and makes the receptor constitutively overactive, pointing back

. << Back to podcast list Strategic Partner(s) Antonella Di Pizio: Computational Pharmacology of Taste model, predict binding-site residues, send them out for mutagenesis, fold the experimental results back

. << Back to podcast list Strategic Partner(s) Bryan Roth: Inside the DARPA Bet on a Non-Psychedelic It reframes the field's task from finding good targets to understanding the biology well enough to connect seller who supplied the compound disagreed, took naloxone, smoked salvia to disprove it, and emailed back project: a non-psychedelic psychedelic for depression 38:21 "I am not uncertain" — the data Bryan won't talk

<< Back to podcast list Strategic Partner(s) Dr. Richard Premont About Dr. Richard Premont "Dr.

<< Back to podcast list Strategic Partner(s) Anything BUT GPCRs with Dr.

<< Back to podcast list Strategic Partner(s) Dr. Richard Premont About Dr. Richard Premont "Dr.

<< Back to podcast list Strategic Partner(s) Dr. Richard Premont About Dr. Richard Premont "Dr.

<< Back to podcast list Strategic Partner(s) Dr. Prasenjit Saha About Dr.

<< Back to podcast list Strategic Partner(s) Dr. Stuart Maudsley About Dr.

<< Back to podcast list Strategic Partner(s) Dr. Richard Premont About Dr. Richard Premont "Dr.

<< Back to podcast list Strategic Partner(s) Dr. Stuart Maudsley About Dr.

<< Back to podcast list Strategic Partner(s) Dr. Bruno Giros About Dr. Bruno Giros Dr.

. << Back to podcast list Strategic Partner(s) Brian Arey - Part 2: GPCR Drug Discovery and the Science "I've spent 25 years pushing back against that. I feel like as scientists, we should be who we are.

. << Back to podcast list Strategic Partner(s) Arun Shukla: How Two Arrestins Regulate 800 GPCRs The Shukla, the question of how two proteins manage 800 others isn't abstract — it's the one that pulled him back

. << Back to podcast list Strategic Partner(s) Alexander Hauser: GPCR Pharmacogenomics and Precision his integrative approach - bridging structural biology, evolutionary data, genetics, and psychiatry - back

. << Back to podcast list Strategic Partner(s) Eleonora Comeo: Fluorescent Ligands and the Pharmacology than confirm receptor binding - they allow researchers to follow receptors through internalization, track resilience, collaboration, and not fearing the unknown 54:44 The dopamine rush that keeps scientists coming back

. << Back to podcast list Strategic Partner(s) Ross Cheloha: Nanobody-GPCR Conjugates and the Engineering For Cheloha, the motivation traces back to a habit he carried from childhood: writing reports on exotic About the Guest Ross Cheloha is a tenure-track investigator at the National Institute of Diabetes and

<< Back to podcast list Strategic Partner(s) Dr. JoAnn Trejo About Dr. JoAnn Trejo Dr.